Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Emerging evidence supports their use as a cessation aid but authors call for further research

Findings suggest electronic cigarettes with nicotine help people stop or reduce smoking when compared to electronic cigarettes without nicotine, but more studies are needed.Jamie Hartmann-Boyce, Nuffield Department of Primary Care Health Sciences, University of Oxford.

Electronic cigarettes can help smokers to stop smoking or significantly reduce their consumption, according to new evidence published in the Cochrane Database of Systematic Reviews.

The review draws on data from two randomised trials and found that while nicotine-containing electronic cigarettes were more effective than a non-nicotine placebo in helping smokers to kick the habit, the results need to be confirmed by further research.

Electronic cigarettes are used by many smokers and have been available for a number of years, with their popularity increasing substantially. Yet little has been known about how effective they are at helping people to stop, or their long-term effects.

Read more (Nuffield Department of Primary Care Health Sciences website)

Similar stories

General anaesthesia should be available for dying patients - medical and ethical experts

General Research

General anaesthesia should be more widely available for patients at the end of their lives, according to Oxford experts in ethics and anaesthesia, according to a paper published by Anaesthesia (a journal of the Association of Anaesthetists).

Risk of rare blood clotting higher for COVID-19 than for vaccines

Coronavirus COVID-19 Research

COVID-19 leads to a several-times higher risk of cerebral venous thrombosis (CVT) blood clots than current COVID-19 vaccines.

Asthma drug budesonide shortens recovery time in non-hospitalised patients with COVID-19

Clinical Trials Coronavirus COVID-19 Research

Inhaled budesonide, a common corticosteroid, is the first widely available, inexpensive drug found to shorten recovery times in COVID-19 patients aged over 50 who are treated at home and in other community settings, reports the PRINCIPLE trial in 1,779 participants.

Link between COVID-19 infection and subsequent mental health and neurological conditions found

Coronavirus COVID-19 General Research

One in three COVID-19 survivors received a neurological or psychiatric diagnosis within six months of infection with the SARS-CoV-2 virus, an observational study of more than 230,000 patient health records published in The Lancet Psychiatry journal estimates. The study looked at 14 neurological and mental health disorders.

New national study of long-term impacts of debilitating lung damage from COVID-19

Coronavirus COVID-19 General Research

A new national study will investigate the long-term effects of lung inflammation and scarring from COVID-19. The study, launched with £2 million of funding from UK Research and Innovation (UKRI), aims to develop treatment strategies and prevent disability.